A recombinant human adenovirus type 5 vectored vaccine co-expression of VP1 and VP2 of chicken anemia virus elicits robust protective immune responses.

ABSTRACT: Chicken anemia virus (CAV) causes significant economic losses in the poultry industry worldwide. As current vaccines do not confer complete protection, the development of a highly effective and safe vaccine is of paramount importance. Control strategies relying on live attenuated vaccines carry a risk of reversion to virulence, while conventional inactivated or subunit vaccines preferentially induce a Th2-biased humoral immune response. There often fail to elicit the critical Th1-mediated cellular immunity required to clear infected cells. This immunological imbalance underscores the need for a vaccine that activates both arms of the adaptive immune system. Here, we constructed a recombinant adenovirus, rAd5-CAV-VP1-VP2, which co-expresses two CAV antigens, leveraging the intrinsic ability

SUBMITTER: Li R 

PROVIDER: S-EPMC12767824 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature